Korea’s Health Ministry Selects 43 Innovative Companies For Tax/Funding Benefits
This article was originally published in PharmAsia News
Executive Summary
Tax credits, priority for government projects and expanded funding opportunities will support 42 Korean firms and Korea-heavy Otsuka Pharmaceutical with R&D expansion
You may also be interested in...
Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence
SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010
Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate
SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe